Plain-English translation of NCT07136012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing whether , a new injectable medication, can help prevent heart attacks and other serious heart events in people at risk. About 11,000 people will be enrolled at sites around the world. Half will receive the medication and half will receive a placebo (a dummy injection with no active drug), and neither participants nor researchers will know which group each person is in.
Lipoprotein(a) is a type of cholesterol particle that can increase your risk of heart disease, but current treatments don't effectively lower it. This medication is designed to reduce lipoprotein(a) levels and potentially prevent first-time heart attacks in people who haven't yet experienced one.
You likely qualify if…
You likely don't qualify if…
You will receive either the new medication or a placebo as an injection under the skin at regular visits. The study will follow you over time to see whether this medication reduces your risk of having a heart attack or needing emergency heart procedures. You'll have blood tests and other routine check-ups to monitor your health throughout the trial.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States